

Curriculum Vitae

NAME: **ROBERTO PIVA**
Born: Turin, Italy
Citizenship: Italian
Phone: +39-334-3400572
E-mail: roberto.piva@unito.it

BIOGRAPHICAL SKETCH

Prof. Roberto Piva is recipient of Honours Degree in Biology, Doctoral Degree in Neurological Sciences and Residency in Clinical Pathology. During the first part of his career he focused his research on the study of the molecular mechanisms of cell death in human and mouse models of neurodegenerative disorders. From 1999 to 2002 he served as a Research Scientist at the Department of Pathology of the New York University where he acquired expertise on cell cycle, protein degradation through the ubiquitin pathway, and on transgenic mouse models. From 2002 to 2003 he was Senior Scientist for a Biotech company where he investigated the anti-tumoral activity of NF- κ B inhibitors in B-cell malignancies. In 2004 he moved to the Centre for Experimental Research in Medicine (CeRMS), University of Turin, where he established his own laboratory as a recipient of the Brain Gain grant program from the Italian Ministry of University and Research (MIUR). Since then, his research has been oriented towards the dissection of the ALK signaling, and on the validation of therapeutic targets for hematological malignancies using a combination of gene expression profiling and functional screenings. In 2007 he was appointed Associate Professor in Laboratory Medicine by the University of Turin, and Adjunct Assistant Professor in Pathology at the New York University School of Medicine. He is author of >60 peer-reviewed publications, Principal Investigator (PI) in several funded research grants, and the supervisor of an independent research team composed of 7 researchers and students.

CURRENT/PAST POSITIONS

2007-to date: Associate Professor, University of Torino, Torino, Italy
2007-to date: Adjunct Assist Prof, New York University School of Medicine, New York, USA
2005-2007: Assist Prof, University of Torino, Torino, Italy
2003-2004: Senior Scientist, Charterhouse Therapeutics Ltd, Roma, Italy
1999-2002: Research Scientist, New York University School of Medicine, New York, USA

EDUCATION

2003-2008: Residency in Clinical Pathology, University of Torino, Torino, Italy
1999-2002: Molecular Oncology program, Department of Pathology, Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, NY, USA
1996-2001: PhD in Neurological Sciences, University of Torino, Torino, Italy
1995-1996: Visiting Scientist, Department of Medical Genetics and Division of Neuropathology, Indiana University, Indianapolis, IN, USA
1993-1995: Fellow in Neuropathology, University of Torino, Torino, Italy
1987-1992: Honours Degree in Biology/Genetics, University of Parma, Parma, Italy

AWARDS AND HONOURS

1993-1995: Fellowship supported by Telethon-Italy

1995-1996: Fellowship supported by the Italian Association for Cancer Research (AIRC)
1996-2000: Fellowship from University of Turin (Ph.D. Program)
1997: Valeria Manetto Award from the Italian Association for Neuropathology (AIN)
1997: Short-term Mobility Fellowship from the Italian National Research Council (CNR): training at the Department of Neuroscience, Brown University, Providence, RI, (USA)
2002: Training Award from the American Association for Cancer Research (AACR)
2004: Fellowship from the “Gigi Ghirotti Association”
2005-2009: Grant from the Italian Ministry of University and Research (MIUR): “Brain Gain Program”
2014: Full Professorship Habilitation in Applied Medical Technologies (06/N1) and Applied Biology (05/F1) from Abilitazione Scientifica Nazionale (ASN)

OTHER

2004-2005: Scientific Consultant: Charterhouse Therapeutics Ltd
2007-2009: Co-founder and Scientific Director of Salus Futura Ltd. and Salus Futura s.r.l.

TEACHING

2000-2004: New York University: “Applied Molecular Biology”
2005-2007: University of Turin: “Histology and cytology techniques”
2008-to date: University of Turin: “Applied Molecular Biology”
2008-to date: University of Turin: “Molecular Biology in Pathology”
2011-to date: University of Turin: “Molecular profiles of proliferative processes”

CLINICAL ACTIVITY

2007-to date: Staff Biologist at the Department of Laboratory Medicine, Division of Pathology, San Giovanni Battista Hospital, Torino, Italy.
Program: identification of genomic signatures and characterization of therapeutic targets in Non-Hodgkin Lymphoma patients.

SUPERVISION ACTIVITIES

2005-2012: 8 Undergraduate students, 4 PhD students, and 2 postdoctoral researchers.
2013-to date: 1 Postdoc, 4 Undergraduate and 4 Phd students at various stages.

MAIN RESEARCH ACTIVITIES

- Signaling networking in lymphomagenesis and tumour maintenance: focus on ALK-STAT3 and NF-kappaB pathways
- In vitro and in vivo preclinical studies for the development of tyrosine kinase and proteasome inhibitors
- Identification and validation of new therapeutic targets in oncology by coupling structural and functional screenings
http://www.dbmss.unito.it/unitoWAR/page/dipartimenti9/D109_en/P254005039091394016602007
- Design of Personalized Treatments for Non Hodgkin Lymphoma (NHL) patients
http://www.unito.it/unitoWAR/page/dipartimenti9/D109_en/P254004939091394016583258
- development of Patient Derived Tumorgraft for the design of new protocols to treat metastatic GIST patients resistant to current treatment
<http://www.mitigate-project.eu/>

PREVIOUS AND EXISTING SUPPORTS

- 2005-2009 EU-FP6 project: RNA Interference Technology as Human Therapeutic Tool (Collaborator)
- 2005-2007 Italian Ministry for University and Research (MIUR): Brain Gain Program (PI); 144.000 €;
- 2006-2008 Piedmont Region: Applied Scientific Research 2004 (CO-PI); 43.000 €;
- 2006-2008 Piedmont Region: Applied Medical Research (PI); 12.000 €;
- 2006-2009 Italian Investment Fund for Basic Research (FIRB): "Cooperation Ita-USA" (CO-PI); 45.000 €;
- 2007-2009 Italian Association for Cancer Research (AIRC): Investigator Grant (PI); 105.000 €;
- 2007-2009 CRT Foundation: Progetto Alfieri (CO-PI); 75.000 €;
- 2007-2010 Piedmont Region: CIPE 2006 (CO-PI); 55.000 €
- 2008-2010 Piedmont Region: Applied Medical Research (PI); 10.000 €
- 2008-2011 Piedmont Region: Converging Technologies (CO-PI); 110.000 €
- 2008-2011 Piedmont Region: Innovative platforms in biotechnology (Collaborator); 130.000 €
- 2009-2011 Piedmont Region: Applied Medical Research (PI); 8.000 €
- 2010-2012 Italian Association for Cancer Research (AIRC): Investigator Grant (PI); 240.000 €
- 2010-2012 Rete Oncologica del Piemonte e Valle d'Aosta: Network Projects (PI); 120.000 €
- 2011-2014 AIRC: Special Program in Clinical Molecular Oncology 5x1000 (Collaborator); 150.000 €
- 2013-2015 Italian Association for Cancer Research (AIRC): Investigator Grant (PI); 300.000 €
- 2013-2015 Italian Investment Fund for Basic Research (FIRB): Future in Research 2012 (Collaborator); 156.000 €
- 2013-2015 University of Torino and Compagnia di San Paolo: Call 2 EU Accelerating Grant (PI); 93.000 €
- 2013-2017 European Community's FP7 Project MITIGATE (Collaborator); 100.000 €
- 2014-2016 CRT Foundation: Richieste Ordinarie 2014 (PI); 80.000 €;

REVIEWER ACTIVITIES

Scientific Journals: FEBS Letters, Blood, Cancer Research, Hematological Oncology, Expert Opinion On Drug Discovery, BMC Cancer, Haematologica, Oncotarget

Grant Proposal: University of Padova, IT

MEMBERSHIPS

American Association for Cancer Research (AACR): Active Member

National Association of Biologists (ONB): Active Member

SELECTED PRESENTATIONS AS INVITED SPEAKER

1998: The JNK/c-Jun pathway is activated in neurodegenerative diseases and is not linked to apoptosis. The Sixth Euroconference on Apoptosis, Stockholm, Sweden

2000: SCF complexes regulate genomic stability and neoplastic transformation. Amersham-Pharmacia, Nerviano, Milano

2001: In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. The Salk Institute, San Diego, USA

2001: SCF complexes regulate genomic stability and neoplastic transformation. Università di Roma Tor Vergata

2003: How can cell cycle perturbation determine neoplastic transformation? IRBM-Merck, Pomezia, Roma

2004: Targeting oncogenic ALK by stable small interfering RNA induces cell death of human Anaplastic Large Cell Lymphoma cells. IFOM, Milano

2005: Identification of genomic and proteomic signatures in lymphomas by inducible shRNA. Centro Congressi Molinette, Torino

2005: Targeting oncogenic ALK by lentiviral small interfering RNA induces growth arrest and apoptosis of human anaplastic large cell lymphoma cells. American and Canadian Academy of Pathology, San Antonio, USA

2007: Insights into the critical role of STAT3 in lymphomas. MBC, Turin

2008: In search of the physiological and oncogenic role of ALK. CEINGE, Naples

2009: Aberrant survival signalling in B cell malignancies. Frascati, Rome

2010: Application of Functional Genomics for the identification of essential genes in cancer cells. Barcelona, ES

2011: Molecular fingerprints of Systemic ALCL. Bellinzona, CH

2012: A wetlab's perspective on Information Overload induced by genome-wide data. MBC, Turin

2013: Functional Approaches for the Validation of Therapeutic Targets in Hematological Malignancies. University of Pavia, Pavia

2014: Signaling network dissection in Anaplastic Large Cell Lymphomas. 5th ERIA Meeting, Triuggio, Monza

2014: Unraveling the wicked games of cancer genomes. Workshop SIC Torino

BIBLIOMETRY

- Peer reviewed articles: 63

- Total Impact Factor (JCR 2011): 438.8

- H index: Google Scholar=33; Scopus=27

- Citations: Google Scholar=3387; Scopus=2254

<http://scholar.google.it/citations?user=u-fr7cAAAAJ>

PEER REVIEWED PUBLICATIONS

1. **Piva R**, Deaglio S, Famà R, Buonincontri R, Scarfò I, Brusca A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri SA, Foà R, Inghirami G, Gaidano G, Rossi D. The krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. *Leukemia*. 2014 Oct 6;PubMed PMID: 25283840.
2. Martinengo C, Poggio T, Menotti M, Scalzo MS, Ambrogio C, Mastini C, Pellegrino E, Riera L, **Piva R**, Ribatti D, Pastorino F, Perri P, Ponzoni M, Wang Q, Voena C, Chiarle R. ALK-dependent control of hypoxia inducible factors mediates tumor growth and metastasis. *Cancer Res*. 2014 Sep 5;PubMed PMID: 25193384.
3. Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA, Pileri A Jr, Mancini M, Rossi M, Ricci F, Gazzola A, Melle F, Mannu C, Ulbar F, Arpinati M, Paulli M, Maeda T, Gibellini D, Pagano L, Pimpinelli N, Santucci M, Cerroni L, Croce CM, Facchetti F, Piccaluga PP, Pileri SA, AIRC 5xMille consortium (Foà R, Chiaretti S, Berardelli F, Falini B, Tiacci E, Inghirami G, **Piva R**, Gaidano G, Rossi D, Pileri S, Piccaluga P). 'Genetics-driven targeted management of lymphoid malignancies and the Italian Registry on Blastic Plasmacytoid Dendritic Cell Neoplasm. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-κB pathway inhibition. *Leukemia*. 2014 Aug;28(8):1606-16. PubMed PMID: 24504027.
4. Saoncella S, Tassone B, Deklic E, Avolio F, Jon C, Tornillo G, De Luca E, Di Iorio E, **Piva R**, Cabodi S, Turco E, Pandolfi PP, Calautti E. Nuclear Akt2 opposes limb keratinocyte stem cell self-renewal by repressing a FOXO-mTORC1 signaling pathway. *Stem Cells*. 2014 Mar;32(3):754-69. PubMed PMID: 24123662.
5. Verdelli D, Nobili L, Todoerti K, Mosca L, Fabris S, D'Anca M, Pellegrino E, **Piva R**, Inghirami G, Capelli C, Introna M, Baldini L, Chiaramonte R, Lombardi L, Neri A. Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line. *Genes Chromosomes Cancer*. 2014 Feb;53(2):154-67. PubMed PMID: 24327544.
6. Peviani M, Tortarolo M, Battaglia E, **Piva R**, Bendotti C. Specific induction of Akt3 in spinal cord motor neurons is neuroprotective in a mouse model of familial amyotrophic lateral sclerosis. *Mol Neurobiol*. 2014 Feb;49(1):136-48. PubMed PMID: 23873136.
7. Spaccarotella E, Pellegrino E, Ferracin M, Ferreri C, Cuccuru G, Liu C, Iqbal J, Cantarella D, Taulli R, Provero P, Di Cunto F, Medico E, Negrini M, Chan WC, Inghirami G, **Piva R**. STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. *Haematologica*. 2014 Jan;99(1):116-24. PubMed PMID: 23975180; PubMed Central PMCID: PMC4007939.
8. Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbò F, **Piva R**, Rancoita PM, Matolcsy A, Timar B, Tousseyn T, Rodríguez-Pinilla SM, Piris MA, Beà S, Campo E, Bhagat G, Swerdlow SH, Rosenwald A, Ponzoni M, Young KH, Piccaluga PP, Dummer R, Pileri S, Zucca E, Inghirami G, Bertoni F. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. *Blood*. 2013 Oct 10;122(15):2683-93. PubMed PMID: 24004669.
9. Bonetti P, Testoni M, Scandurra M, Ponzoni M, **Piva R**, Mensah AA, Rinaldi A, Kwee I, Tibiletti MG, Iqbal J, Greiner TC, Chan WC, Gaidano G, Piris MA, Cavalli F, Zucca E, Inghirami G, Bertoni F. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. *Blood*. 2013 Sep 26;122(13):2233-41. PubMed PMID: 23926301.
10. Liu C, Iqbal J, Teruya-Feldstein J, Shen Y, Dabrowska MJ, Dybkaer K, Lim MS, **Piva R**, Barreca A, Pellegrino E, Spaccarotella E, Lachel CM, Kucuk C, Jiang CS, Hu X, Bhagavathi S, Greiner TC,

- Weisenburger DD, Aoun P, Perkins SL, McKeithan TW, Inghirami G, Chan WC. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. *Blood*. 2013 Sep 19;122(12):2083-92. PubMed PMID: 23801630; PubMed Central PMCID: PMC3778551.
11. Piccaluga PP, Fuligni F, De Leo A, Bertuzzi C, Rossi M, Bacci F, Sabattini E, Agostinelli C, Gazzola A, Laginestra MA, Mannu C, Sapienza MR, Hartmann S, Hansmann ML, **Piva R**, Iqbal J, Chan JC, Weisenburger D, Vose JM, Bellei M, Federico M, Inghirami G, Zinzani PL, Pileri SA. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. *J Clin Oncol*. 2013 Aug 20;31(24):3019-25. PubMed PMID: 23857971.
 12. Tabbò F, Ponzoni M, Rabadan R, Bertoni F, Inghirami G, European T-cell Lymphoma Study Group (Aliberti S, Barreca A, Bessone L, Crescenzo R, Di Giacomo F, Gaudio M, Inghirami G, Landra I, Lasorsa E, Machiorlatti R, Mereu E, Messina K, Novero D, Pellegrino E, Pich A, **Piva R**, Scarfó I, Spaccarotella E, Tabbò F, Todaro M, Ubezzi I, Urigu S, Vittone F, Abage F, Ficarra E, Acquaviva A, Ponzoni M, Stella C, Agostinelli C, Piccaluga PP, Pileri S, Falini B, Tiacci E, Bertoni F, Boi M, Kwee I). Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. *Curr Opin Hematol*. 2013 Jul;20(4):374-81. PubMed PMID: 23673339; PubMed Central PMCID: PMC4121055.
 13. Abate F, Acquaviva A, Ficarra E, **Piva R**, Macii E. Gelsius: a literature-based workflow for determining quantitative associations between genes and biological processes. *IEEE/ACM Trans Comput Biol Bioinform*. 2013 May-Jun;10(3):619-31. PubMed PMID: 24091396.
 14. Laimer D, Dolznig H, Kollmann K, Vesely PW, Schleder M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagner S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messina K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, **Piva R**, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. *Nat Med*. 2012 Nov;18(11):1699-704. PubMed PMID: 23064464.
 15. Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E, Ponzoni M, Zamò A, Iqbal J, Piccaluga PP, Neri A, Chan WC, Pileri S, Bertoni F, Inghirami G, **Piva R**, European T-Cell Lymphoma Study Group. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. *Blood*. 2012 Aug 9;120(6):1274-81. PubMed PMID: 22740451.
 16. Peviani M, Kurosaki M, Terao M, Lidonnici D, Gensano F, Battaglia E, Tortarolo M, **Piva R**, Bendotti C. Lentiviral vectors carrying enhancer elements of Hb9 promoter drive selective transgene expression in mouse spinal cord motor neurons. *J Neurosci Methods*. 2012 Mar 30;205(1):139-47. PubMed PMID: 22245491.
 17. Kwee I, Rinaldi A, Rancoita P, Rossi D, Capello D, Forconi F, Giuliani N, **Piva R**, Inghirami G, Gaidano G, Zucca E, Bertoni F. Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array. *Br J Haematol*. 2012 Feb;156(3):354-7. PubMed PMID: 22118580.
 18. Tabbó F, Barreca A, **Piva R**, Inghirami G, European T-Cell Lymphoma Study Group. ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. *Front Oncol*. 2012;2:41. PubMed PMID: 22649787; PubMed Central PMCID: PMC3355932.
 19. Inghirami G, Pileri SA, European T-Cell Lymphoma Study Group. Anaplastic large-cell lymphoma. *Semin Diagn Pathol*. 2011 Aug;28(3):190-201. PubMed PMID: 21850985.
 20. Barreca A, Lasorsa E, Riera L, Machiorlatti R, **Piva R**, Ponzoni M, Kwee I, Bertoni F, Piccaluga PP, Pileri SA, Inghirami G, European T-Cell Lymphoma Study Group. Anaplastic lymphoma kinase in human cancer. *J Mol Endocrinol*. 2011 Aug;47(1):R11-23. PubMed PMID: 21502284.
 21. **Piva R**, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, Fornari A, Martinoglio B, Medico E, Zamò A, Facchetti F, Ponzoni M, Geissinger E, Rosenwald A, Müller-Hermelink HK, De Wolf-Peeters C, Piccaluga PP, Pileri S, Neri A, Inghirami G. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. *J Clin Oncol*. 2010 Mar 20;28(9):1583-90. PubMed PMID: 20159827.
 22. Piccaluga PP, Gazzola A, Mannu C, Agostinelli C, Bacci F, Sabattini E, Sagrarnoso C, **Piva R**, Roncolato F, Inghirami G, Pileri SA. Pathobiology of anaplastic large cell lymphoma. *Adv Hematol*. 2010;PubMed PMID: 21331150; PubMed Central PMCID: PMC3038421.
 23. Belardo G, **Piva R**, Santoro MG. Heat stress triggers apoptosis by impairing NF-kappaB survival signaling in malignant B cells. *Leukemia*. 2010 Jan;24(1):187-96. PubMed PMID: 19924145.
 24. Fornari A, **Piva R**, Chiarle R, Novero D, Inghirami G. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?. *Hematol Oncol*. 2009 Dec;27(4):161-70. PubMed PMID: 19358142.
 25. Regis G, Icardi L, Conti L, Chiarle R, **Piva R**, Giovarelli M, Poli V, Novelli F. IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. *Leukemia*. 2009 Nov;23(11):2102-8. PubMed PMID: 19626047.
 26. **Piva R**, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Streponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ova

- H, Bernareggi A, Inghirami G. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. *Blood*. 2008 Mar 1;111(5):2765-75. PubMed PMID: 18057228.
27. Battaglia F, Delfino S, Merello E, Puppo M, **Piva R**, Varesio L, Bosco MC. Hypoxia transcriptionally induces macrophage-inflammatory protein-3alpha/CCL-20 in primary human mononuclear phagocytes through nuclear factor (NF)-kappaB. *J Leukoc Biol*. 2008 Mar;83(3):648-62. PubMed PMID: 18089854.
 28. Chiarle R, Voena C, Ambrogio C, **Piva R**, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. *Nat Rev Cancer*. 2008 Jan;8(1):11-23. PubMed PMID: 18097461.
 29. Di Stefano P, Damiano L, Cabodi S, Aramu S, Tordella L, Praduroux A, **Piva R**, Cavallo F, Forni G, Silengo L, Tarone G, Turco E, Defilippi P. p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. *EMBO J*. 2007 Jun 20;26(12):2843-55. PubMed PMID: 17525734; PubMed Central PMCID: PMC1894765.
 30. Primo L, di Blasio L, Roca C, Droetto S, **Piva R**, Schaffhausen B, Bussolino F. Essential role of PDK1 in regulating endothelial cell migration. *J Cell Biol*. 2007 Mar 26;176(7):1035-47. PubMed PMID: 17371830; PubMed Central PMCID: PMC2064087.
 31. **Piva R**, Pellegrino E, Inghirami G. Identification and validation of the anaplastic large cell lymphoma signature. *Adv Exp Med Biol*. 2007;604:129-36. PubMed PMID: 17695725.
 32. **Piva R**, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, Costa G, Ruggeri BA, Cheng M, Chiarle R, Palestro G, Neri A, Inghirami G. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. *J Clin Invest*. 2006 Dec;116(12):3171-82. PubMed PMID: 17111047; PubMed Central PMCID: PMC1636692.
 33. Ciucci A, Gianferretti P, **Piva R**, Guyot T, Snape TJ, Roberts SM, Santoro MG. Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkkappaB kinase/nuclear factor-kappaB pathway. *Mol Pharmacol*. 2006 Nov;70(5):1812-21. PubMed PMID: 16908599.
 34. **Piva R**, Belardo G, Santoro MG. NF-kappaB: a stress-regulated switch for cell survival. *Antioxid Redox Signal*. 2006 Mar-Apr;8(3-4):478-86. PubMed PMID: 16677091.
 35. **Piva R**, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. *Blood*. 2006 Jan 15;107(2):689-97. PubMed PMID: 16189272; PubMed Central PMCID: PMC1895619.
 36. Ambrogio C, Voena C, Manazza AD, **Piva R**, Riera L, Barberis L, Costa C, Tarone G, Defilippi P, Hirsch E, Boeri Erba E, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. *Blood*. 2005 Dec 1;106(12):3907-16. PubMed PMID: 16105984; PubMed Central PMCID: PMC1895100.
 37. Inghirami G, Chiarle R, Simmons WJ, **Piva R**, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. *Cell Cycle*. 2005 Sep;4(9):1131-3. PubMed PMID: 16082218.
 38. **Piva R**, Gianferretti P, Ciucci A, Taulli R, Belardo G, Santoro MG. 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. *Blood*. 2005 Feb 15;105(4):1750-8. PubMed PMID: 15498850.
 39. Bendotti C, Atzori C, **Piva R**, Tortarolo M, Strong MJ, DeBiasi S, Migheli A. Activated p38MAPK is a novel component of the intracellular inclusions found in human amyotrophic lateral sclerosis and mutant SOD1 transgenic mice. *J Neuropathol Exp Neurol*. 2004 Feb;63(2):113-9. PubMed PMID: 14989597.
 40. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, Simmons WJ, Dhall G, Howes J, **Piva R**, Inghirami G. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. *Blood*. 2003 Mar 1;101(5):1919-27. PubMed PMID: 12424201.
 41. **Piva R**, Liu J, Chiarle R, Podda A, Pagano M, Inghirami G. In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. *Mol Cell Biol*. 2002 Dec;22(23):8375-87. PubMed PMID: 12417738; PubMed Central PMCID: PMC134052.
 42. Schiffer D, Cavalla P, Fiano V, Ghimenti C, **Piva R**. Inverse relationship between p27/Kip1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot. *Neurosci Lett*. 2002 Aug 9;328(2):125-8. PubMed PMID: 12133571.
 43. Chiarle R, Fan Y, **Piva R**, Boggino H, Skolnik J, Novero D, Palestro G, De Wolf-Peeters C, Chilosi M, Pagano M, Inghirami G. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. *Am J Pathol*. 2002 Apr;160(4):1457-66. PubMed PMID: 11943729; PubMed Central PMCID: PMC1867227.
 44. Zamo A, Chiarle R, **Piva R**, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. *Oncogene*. 2002 Feb 7;21(7):1038-47. PubMed PMID: 11850821.

45. Atzori C, Ghetti B, **Piva R**, Srinivasan AN, Zolo P, Delisle MB, Mirra SS, Migheli A. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. *J Neuropathol Exp Neurol.* 2001 Dec;60(12):1190-7. PubMed PMID: 11764091.
46. Audero E, Cascone I, Zanon I, Previtali SC, **Piva R**, Schiffer D, Bussolino F. Expression of angiopoietin-1 in human glioblastomas regulates tumor-induced angiogenesis: in vivo and in vitro studies. *Arterioscler Thromb Vasc Biol.* 2001 Apr;21(4):536-41. PubMed PMID: 11304469.
47. Chilosi M, Chiarle R, Lestani M, Menestrina F, Montagna L, Ambrosetti A, Prolla G, Pizzolo G, Doglioni C, **Piva R**, Pagano M, Inghirami G. Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. *Br J Haematol.* 2000 Oct;111(1):263-71. PubMed PMID: 11091210.
48. Cavalla P, **Piva R**, Bortolotto S, Grosso R, Cancelli I, Chiò A, Schiffer D. p27/kip1 expression in oligodendrogliomas and its possible prognostic role. *Acta Neuropathol.* 1999 Dec;98(6):629-34. PubMed PMID: 10603039.
49. Migheli A, Atzori C, **Piva R**, Tortarolo M, Girelli M, Schiffer D, Bendotti C. Lack of apoptosis in mice with ALS. *Nat Med.* 1999 Sep;5(9):966-7. PubMed PMID: 10470053.
50. Migheli A, **Piva R**, Casolino S, Atzori C, Dlouhy SR, Ghetti B. A cell cycle alteration precedes apoptosis of granule cell precursors in the weaver mouse cerebellum. *Am J Pathol.* 1999 Aug;155(2):365-73. PubMed PMID: 10433930; PubMed Central PMCID: PMC1866868.
51. **Piva R**, Cancelli I, Cavalla P, Bortolotto S, Dominguez J, Draetta GF, Schiffer D. Proteasome-dependent degradation of p27/kip1 in gliomas. *J Neuropathol Exp Neurol.* 1999 Jul;58(7):691-6. PubMed PMID: 10411338.
52. Schiffer D, Bortolotto S, Bosone I, Cancelli I, Cavalla P, Schiffer P, **Piva R**. Cell-cycle inhibitor p27/Kip-1 expression in non-astrocytic and non-oligodendrocytic human nervous system tumors. *Neurosci Lett.* 1999 Apr 2;264(1-3):29-32. PubMed PMID: 10320006.
53. Migheli A, Cordera S, Bendotti C, Atzori C, **Piva R**, Schiffer D. S-100beta protein is upregulated in astrocytes and motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis. *Neurosci Lett.* 1999 Feb 12;261(1-2):25-8. PubMed PMID: 10081918.
54. Wei J, Hodes ME, **Piva R**, Feng Y, Wang Y, Ghetti B, Dlouhy SR. Characterization of murine Girk2 transcript isoforms: structure and differential expression. *Genomics.* 1998 Aug 1;51(3):379-90. PubMed PMID: 9721208.
55. Cavalla P, Dutto A, **Piva R**, Richiardi P, Grosso R, Schiffer D. Cyclin D1 expression in gliomas. *Acta Neuropathol.* 1998 Feb;95(2):131-5. PubMed PMID: 9498046.
56. **Piva R**, Cavalla P, Bortolotto S, Cordera S, Grosso R, Richiardi P, Dutto A, Schiffer D. CDKN2/p16 inactivation and p16 immunohistochemistry in astrocytic gliomas. *Int J Oncol.* 1998 Jan;12(1):55-8. PubMed PMID: 9454886.
57. Migheli A, **Piva R**, Atzori C, Troost D, Schiffer D. c-Jun, JNK/SAPK kinases and transcription factor NF-kappa B are selectively activated in astrocytes, but not motor neurons, in amyotrophic lateral sclerosis. *J Neuropathol Exp Neurol.* 1997 Dec;56(12):1314-22. PubMed PMID: 9413280.
58. Migheli A, **Piva R**, Wei J, Attanasio A, Casolino S, Hodes ME, Dlouhy SR, Bayer SA, Ghetti B. Diverse cell death pathways result from a single missense mutation in weaver mouse. *Am J Pathol.* 1997 Dec;151(6):1629-38. PubMed PMID: 9403713; PubMed Central PMCID: PMC1858371.
59. **Piva R**, Cavalla P, Bortolotto S, Cordera S, Richiardi P, Schiffer D. p27/kip1 expression in human astrocytic gliomas. *Neurosci Lett.* 1997 Oct 3;234(2-3):127-30. PubMed PMID: 9364514.
60. Migheli A, Mongini T, Doriguzzi C, Chiadò-Piat L, **Piva R**, Ugo I, Palmucci L. Muscle apoptosis in humans occurs in normal and denervated muscle, but not in myotonic dystrophy, dystrophinopathies or inflammatory disease. *Neurogenetics.* 1997 Sep;1(2):81-7. PubMed PMID: 10732808.
61. Schiffer D, Dutto A, Cavalla P, Chiò A, Migheli A, **Piva R**. Role of apoptosis in the prognosis of oligodendrogliomas. *Neurochem Int.* 1997 Aug;31(2):245-50. PubMed PMID: 9220457.
62. Wei J, Dlouhy SR, Bayer S, **Piva R**, Verina T, Wang Y, Feng Y, Dupree B, Hodes ME, Ghetti B. In situ hybridization analysis of Girk2 expression in the developing central nervous system in normal and weaver mice. *J Neuropathol Exp Neurol.* 1997 Jul;56(7):762-71. PubMed PMID: 9210872.
63. Migheli A, Cavalla P, **Piva R**, Giordana MT, Schiffer D. bcl-2 protein expression in aged brain and neurodegenerative diseases. *Neuroreport.* 1994 Oct 3;5(15):1906-8. PubMed PMID: 7841373.

Nome: **Roberto Piva**

Data di Nascita: 21 settembre 1966

Luogo: Torino

Cittadinanza: Italiana

Tel: 011-6334149

E-mail: roberto.piva@unito.it

Posizione Attuale: Professore Associato confermato, Università di Torino; Adjunct Assistant Professor, New York University School of Medicine

Laureato in Scienze Biologiche presso l'Università di Parma nel 1992, Dottore di Ricerca in Scienze Neurologiche, specialista in Patologia Clinica. Dal 1993 al 1998 ha svolto attività di ricerca presso il Dip. di Neuroscienze dell'Università di Torino. Dal 1999 al 2004 è stato Ricercatore presso il Dip. di Patologia, New York University, NY (USA). Dal 2002 al 2003 Senior Scientist presso la filiale Italiana di Charterhouse Therapeutics Ltd., Università di Roma Tor Vergata, Roma. Dal 2005 al 2007 Professore a Contratto presso il Dip. di Scienze Biomediche e Oncologia Umana, Università di Torino, ove ha svolto attività didattica e di ricerca nell'ambito del programma "Rientro dei Cervelli". Dal 2007 è Professore Associato presso l'Università di Torino e Adjunct Assistant Professor alla School of Medicine della New York University. Il Prof. Roberto Piva, possiede una notevole esperienza di ricerca in oncologia molecolare, in particolare, nello studio di proteine coinvolte nella regolazione del ciclo di divisione cellulare, nella degradazione mediata dall'ubiquitina, in modelli in vitro e in vivo di linfomi umani. Recentemente, ha associato le tecniche di espressione genica su microchip all'interferenza a RNA per l'identificazione e la validazione di nuovi bersagli terapeutici nelle neoplasie ematologiche. E' autore di numerose pubblicazioni su riviste scientifiche internazionali "peer-reviewed" (63 articoli, indice H: 27) e titolare di numerosi progetti di ricerca (MIUR, Regione Piemonte, AIRC, FIRB). Svolge attività didattica nei Corsi di Laurea in Tecniche di Laboratorio Biomedico, Scienze delle Professioni Sanitarie Tecniche Diagnostiche, e Biotecnologie Molecolari. Afferisce in qualità di dirigente di fascia PS alla SC Anatomia e Istologia Patologica 2U ove si occupa dello sviluppo di un programma di oncogenomica per la stadiazione dei malati oncologici e la predizione della risposta alla terapia.

PERCORSO SCIENTIFICO-PROFESSIONALE

2007-a oggi: Adjunct Assistant Professor, Department of Pathology, New York University Langone Medical Center, New York, (NY), USA;

2005-2007: Professore a Contratto, Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino;

2002-2004: Senior Scientist, Charterhouse Therapeutics Ltd., Filiale Italiana, Università di Roma Tor Vergata, Roma;

2001-2002: Research Scientist, Department of Pathology, Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, NY;

1999-2000: Assistant Research Scientist, Department of Pathology, Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, NY;

1995-1996: Visiting Scientist, Department of Medical Genetics and Division of Neuropathology, Indiana University, Indianapolis; IN, (USA);

1993-1998: Ricercatore borsista, Dipartimento di Neuroscienze, Università di Torino;

ISTRUZIONE

1985: Diploma di Maturità Scientifica, Liceo "P. Gobetti", Torino

1992: Laurea in Scienze Biologiche, Università di Parma (110/110)

1993: Abilitazione all'esercizio della professione di Biologo, Università di Parma

2000: Dottorato di Ricerca in Scienze Neurologiche, Università di Torino

2008: Specializzazione in Patologia Clinica, Università di Torino (70/70)

PREMI E RICONOSCIMENTI PER L'ATTIVITÀ SCIENTIFICA

1993-1995: Borsa di Studio, Associazione per la Ricerca Biomedica finanziata da Telethon

1995-1996: Borsa di Studio, Gruppo di Cooperazione in Cancerologia finanziata da AIRC

1996-2000: Borsa di Studio, Dottorato di Ricerca in Scienze Neurologiche, Università di Torino

1997: Premio "Valeria Manetto", Associazione Italiana di Neuropatologia (AIN)

1997: Borsa di Studio per mobilità internazionale, Consiglio Nazionale delle Ricerche (CNR)

2002: Scholar-In Training Award, Associazione Americana per la Ricerca sul Cancro (AACR)

2004: Borsa di Studio del Comitato Regionale Gigi Ghirotti

2005-2009: Contratto di collaborazione alla didattica e alla ricerca, MIUR (Chiamata di studiosi dall'estero)

2014: Abilitazione Scientifica al ruolo di Professore di I Fascia in Medicina di laboratorio (06/N1) e in Biologia Applicata (05/F1)

RISULTATI OTTENUTI NEL TRASFERIMENTO TECNOLOGICO

2004-2005: Consulente Scientifico Charterhouse Therapeutics Ltd.

2007-2009: Co-fondatore e Direttore Scientifico di Salus Futura Ltd. e di Salus Futura s.r.l.

ATTIVITÀ DIDATTICA

2000-2004: Istruttore di Tecniche di Biologia Molecolare (New York University School of Medicine)

2005-2007: Docente di Tecniche Istocitologiche, Corso di Laurea in Tecniche di Laboratorio Biomedico (Università di Torino)

2008-a oggi: Responsabile del Corso Integrato in Anatomia Patologica e Oncologia, Corso di Laurea in Tecniche di Laboratorio Biomedico (Torino)

2008-a oggi: Docente di Biologia Molecolare in Patologia, Corso di Laurea in Tecniche di Laboratorio Biomedico (Torino)

2008-a oggi: Docente di Approfondimenti di Biologia Molecolare Applicata, Corso di Laurea Specialistica in Scienze Tecniche Diagnostiche (Torino)

2010-a oggi: Membro Collegio Docenti Dottorato in Medicina Molecolare (Torino)

2011-a oggi: Docente di Profili molecolari nei processi proliferativi, Scuola Universitaria Interfacoltà per le Biotecnologie

2011-a oggi: Docente di Scienze Tecniche di Medicina di Laboratorio, Scuola di Specializzazione in Malattie dell'Apparato Respiratorio

ATTIVITÀ ASSISTENZIALE

2007-a oggi: Dirigente Biologo presso la Struttura Complessa Anatomia e Istologia Patologica 2U dell'Azienda Ospedaliera Città della Salute e della Scienza di Torino ove si occupa dello sviluppo di un programma di oncogenomica per la stadiazione dei malati oncologici e la predizione della risposta alla terapia.

ATTIVITÀ DI PEER-REVIEWER PER RIVISTE SCIENTIFICHE

FEBS Letters, Blood, Cancer Research, Translational Oncogenomics, Genetics and Molecular Biology, Biochemistry, Hematological Oncology, Expert Opinion On Drug Discovery, BMC Cancer

AFFILIAZIONI

American Association for Cancer Research (AACR)

Ordine Nazionale dei Biologi (ONB)

PRESENTAZIONI ORALI SU INVITO

1996: Il topo weaver: un modello di eterogeneità di morte cellulare. Apoptosi 1996, Torino

1996: Pattern of cell death and Girk2 expression in weaver mouse. 12th lecture course on biophysics and molecular biology, Cividale del Friuli (UD)

1997: Molecular genetic and immunohistochemical analysis of p16/INK4a in astrocytic gliomas Associazione Italiana di Neuropatologia, Pisa

1998: Cell cycle-related proteins and apoptosis in weaver mouse cerebellum. Associazione Italiana di Neuropatologia, Como

1998: The JNK/c-Jun pathway is activated in neurodegenerative diseases and is not linked to apoptosis. The Sixth Euroconference on Apoptosis, Stockholm, Sweden

2000: SCF complexes regulate genomic stability and neoplastic transformation. Amersham-Pharmacia, Nerviano, Milano

2001: In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. The Salk Institute, San Diego, USA

2001: SCF complexes regulate genomic stability and neoplastic transformation. Università di Roma Tor Vergata

2003: How can cell cycle perturbation determine neoplastic transformation? IRBM-Merck, Pomezia, Roma

2004: Targeting oncogenic ALK by stable small interfering RNA induces cell death of human Anaplastic Large Cell Lymphoma cells. IFOM, Milano

2005: Identification of genomic and proteomic signatures in lymphomas by inducible shRNA. Centro Congressi Molinette, Torino

2005: Impiego della tecnica dell'interferenza a RNA in oncologia per la validazione di bersagli terapeutici e per la caratterizzazione di profili di espressione genica. Focus sulle Biotecnologie: RNA interference. Centro Congressi Palazzo delle Stelline, Milano

2005: Targeting oncogenic ALK by lentiviral small interfering RNA induces growth arrest and apoptosis of human anaplastic large cell lymphoma cells. American and Canadian Academy of Pathology, San Antonio, USA

2006: Ruolo fisiologico e patologico della tirosina cinasi ALK. Istituto Mario Negri, Milano

2006: Dissezione delle vie di segnalazione fisiologiche e patologiche della tirosina cinasi ALK. Università di Roma Tor Vergata, Roma

2007: Insights into the central role of STAT3 in the T-cell lymphomagenesis. STAT factors and cancer minisymposium. MBC, Università di Torino

2007: The good, the bad, and the ugly of gene silencing. RNA interference workshop. CeRMS, Università di Torino

2008: In search of the physiological and oncogenic role of the Anaplastic Lymphoma Kinase. CEINGE, Naples 2008 In search of the physiological and oncogenic role of the Anaplastic Lymphoma Kinase. CEINGE, Naples

2009: Aberrant survival signalling in B cell malignancies. The stress response in tumor cell signalling workshop. Frascati, Rome

2010: Application of Functional Genomics for the identification of essential genes in cancer cells. European functional genomics user meeting. Barcelona, SPAIN

2011: Molecular fingerprints of Systemic ALCL. Bellinzona, CH

2012: A wetlab's perspective on Information Overload induced by genome-wide data. MBC, Torino

2013: Functional Approaches for the Validation of Therapeutic Targets in Hematological Malignancies. University of Pavia, Pavia

FINANZIAMENTI

2005-2009: MIUR, programma "Rientro dei cervelli"
2006-2008: Regione Piemonte, Ricerca scientifica applicata 2004
2006-2009: FIRB, Accordo bilaterale Italia-USA, Responsabile Unità di Ricerca
2006-2008: AIRC, titolare progetto di ricerca
2006-2008: Regione Piemonte, Ricerca Sanitaria Finalizzata 2006
2007-2010: Regione Piemonte, CIPE 2006
2007-2009: CRT, Progetto Alfieri
2008-2009: Regione Piemonte, Ricerca Sanitaria Finalizzata 2008
2008-2009: Università di Torino, Ricerca Finanziata dall'Università (ex 60%)
2008-2011: Regione Piemonte, Converging Technologies 2007
2009-2010: Università di Torino, Ricerca Finanziata dall'Università (ex 60%)
2009-2010: Regione Piemonte, Ricerca Sanitaria Finalizzata 2009
2009-2011: AIRC, titolare progetto di ricerca
2010-2012: Rete Oncologica del Piemonte e Valle d'Aosta, titolare progetto di ricerca
2010-2014: AIRC, Programma di Oncologia Clinica Molecolare 5 per mille Collaboratore unità Inghirami
2012-2016: Firb Futuro In Ricerca 2012 Collaboratore Unità Deaglio
2013-2015: AIRC, titolare progetto di ricerca
2014-2014: Fondazione CRT, titolare progetto di ricerca

INDICI BIBLIOMETRICI

-Lavori in extenso su riviste internazionali con Impact Factor: 63
-Impact Factor Totale (JCR 2012): 438,8
-H index: Google Scholar=33; Scopus=27
-Citazioni Totali: Google Scholar=3387; Scopus=2254
http://scholar.google.it/citations?user=_u-fr7cAAAAJ

PUBBLICAZIONI SCIENTIFICHE

1. **Piva R**, Deaglio S, Famà R, Buonincontri R, Scarfò I, Brusca A, Mereu E, Serra S, Spina V, Brusa D, Garaffo G, Monti S, Dal Bo M, Marasca R, Arcaini L, Neri A, Gattei V, Paulli M, Tiacci E, Bertoni F, Pileri SA, Foà R, Inghirami G, Gaidano G, Rossi D. The krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. *Leukemia*. 2014 Oct 6; PubMed PMID: 25283840.
2. Martinengo C, Poggio T, Menotti M, Scalzo MS, Ambrogio C, Mastini C, Pellegrino E, Riera L, **Piva R**, Ribatti D, Pastorino F, Perri P, Ponzoni M, Wang Q, Voena C, Chiarle R. ALK-dependent control of hypoxia inducible factors mediates tumor growth and metastasis. *Cancer Res*. 2014 Sep 5; PubMed PMID: 25193384.
3. Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA, Pileri A Jr, Mancini M, Rossi M, Ricci F, Gazzola A, Melle F, Mannu C, Ulbar F, Arpinati M, Paulli M, Maeda T, Gibellini D, Pagano L, Pimpinelli N, Santucci M, Cerroni L, Croce CM, Facchetti F, Piccaluga PP, Pileri SA, AIRC 5xMille consortium (Foà R, Chiaretti S, Berardelli F, Falini B, Tiacci E, Inghirami G, **Piva R**, Gaidano G, Rossi D, Pileri S, Piccaluga P). 'Genetics-driven targeted management of lymphoid malignancies and the Italian Registry on Blastic Plasmacytoid Dendritic Cell Neoplasm. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF- κ B pathway inhibition. *Leukemia*. 2014 Aug;28(8):1606-16. PubMed PMID: 24504027.
4. Saoncella S, Tassone B, Deklic E, Avolio F, Jon C, Tornillo G, De Luca E, Di Iorio E, **Piva R**, Cabodi S, Turco E, Pandolfi PP, Calautti E. Nuclear Akt2 opposes limbal keratinocyte stem cell self-renewal by repressing a FOXO-mTORC1 signaling pathway. *Stem Cells*. 2014 Mar;32(3):754-69. PubMed PMID: 24123662.
5. Verdelli D, Nobili L, Todoerti K, Mosca L, Fabris S, D'Anca M, Pellegrino E, **Piva R**, Inghirami G, Capelli C, Introna M, Baldini L, Chiaramonte R, Lombardi L, Neri A. Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line. *Genes Chromosomes Cancer*. 2014 Feb;53(2):154-67. PubMed PMID: 24327544.
6. Peviani M, Tortarolo M, Battaglia E, **Piva R**, Bendotti C. Specific induction of Akt3 in spinal cord motor neurons is neuroprotective in a mouse model of familial amyotrophic lateral sclerosis. *Mol Neurobiol*. 2014 Feb;49(1):136-48. PubMed PMID: 23873136.
7. Spaccarotella E, Pellegrino E, Ferracin M, Ferreri C, Cuccuru G, Liu C, Iqbal J, Cantarella D, Taulli R, Provero P, Di Cunto F, Medico E, Negrini M, Chan WC, Inghirami G, **Piva R**. STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. *Haematologica*. 2014 Jan;99(1):116-24. PubMed PMID: 23975180; PubMed Central PMCID: PMC4007939.
8. Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbò F, **Piva R**, Rancoita PM, Matolcsy A, Timar B, Toussey T, Rodríguez-Pinilla SM, Piris MA, Beà S, Campo E, Bhagat G, Swerdlow SH, Rosenwald A, Ponzoni M, Young KH, Piccaluga PP, Dummer R, Pileri S, Zucca E, Inghirami G, Bertoni F. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. *Blood*. 2013 Oct 10;122(15):2683-93. PubMed PMID: 24004669.
9. Bonetti P, Testoni M, Scandurra M, Ponzoni M, **Piva R**, Mensah AA, Rinaldi A, Kwee I, Tibiletti MG, Iqbal J, Greiner TC, Chan WC, Gaidano G, Piris MA, Cavalli F, Zucca E, Inghirami G, Bertoni F. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. *Blood*. 2013 Sep 26;122(13):2233-41. PubMed PMID: 23926301.
10. Liu C, Iqbal J, Teruya-Feldstein J, Shen Y, Dabrowska MJ, Dybkaer K, Lim MS, **Piva R**, Barreca A, Pellegrino E, Spaccarotella E, Lachel CM, Kucuk C, Jiang CS, Hu X, Bhagavathi S, Greiner TC, Weisenburger DD, Aoun P, Perkins SL, McKeithan TW, Inghirami G, Chan WC. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. *Blood*. 2013 Sep 19;122(12):2083-92. PubMed PMID: 23801630; PubMed Central PMCID: PMC3778551.
11. Piccaluga PP, Fuligni F, De Leo A, Bertuzzi C, Rossi M, Bacci F, Sabattini E, Agostinelli C, Gazzola A, Laginestra MA, Mannu C, Sapienza MR, Hartmann S, Hansmann ML, **Piva R**, Iqbal J, Chan JC, Weisenburger D, Vose JM, Bellei M, Federico M, Inghirami G, Zinzani PL, Pileri SA. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. *J Clin Oncol*. 2013 Aug 20;31(24):3019-25. PubMed PMID: 23857971.
12. Tabbò F, Ponzoni M, Rabadan R, Bertoni F, Inghirami G, European T-cell Lymphoma Study Group (Aliberti S, Barreca A, Bessone L, Crescenzo R, Di Giacomo F, Gaudiano M, Inghirami G, Landra I, Lasorsa E, Machiorlatti R, Mereu E, Messana K, Novero D, Pellegrino E, Pich A, **Piva R**, Scarfò I, Spaccarotella E, Tabbò F, Todaro M, Ubezzi I, Urigo S, Vittone F, Abage F, Ficarra E, Acquaviva A, Ponzoni M, Stella C, Agostinelli C, Piccaluga PP, Pileri S, Falini B, Tiacci E, Bertoni F, Boi M, Kwee I). Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. *Curr Opin Hematol*. 2013 Jul;20(4):374-81. PubMed PMID: 23673339; PubMed Central PMCID: PMC4121055.
13. Abate F, Acquaviva A, Ficarra E, **Piva R**, Macii E. Gelsius: a literature-based workflow for determining quantitative associations between genes and biological processes. *IEEE/ACM Trans Comput Biol Bioinform*. 2013 May-Jun;10(3):619-31. PubMed PMID: 24091396.
14. Laimer D, Dolznig H, Kollmann K, Vesely PW, Schleder M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagner S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, **Piva R**, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. *Nat Med*. 2012 Nov;18(11):1699-704. PubMed PMID: 23064464.
15. Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E, Ponzoni M, Zamò A, Iqbal J, Piccaluga PP, Neri A, Chan WC, Pileri S, Bertoni F, Inghirami G, **Piva R**, European T-Cell Lymphoma Study Group. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. *Blood*. 2012 Aug 9;120(6):1274-81. PubMed PMID: 22740451.
16. Peviani M, Kurosaki M, Terao M, Lidonnici D, Gensano F, Battaglia E, Tortarolo M, **Piva R**, Bendotti C. Lentiviral vectors carrying enhancer elements of Hb9 promoter drive selective transgene expression in mouse spinal cord motor neurons. *J Neurosci Methods*. 2012 Mar 30;205(1):139-47. PubMed PMID: 22245491.
17. Kwee I, Rinaldi A, Rancoita P, Rossi D, Capello D, Forconi F, Giuliani N, **Piva R**, Inghirami G, Gaidano G, Zucca E, Bertoni F. Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array. *Br J Haematol*. 2012 Feb;156(3):354-7. PubMed PMID: 22118580.
18. Tabbò F, Barreca A, **Piva R**, Inghirami G, European T-Cell Lymphoma Study Group. ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. *Front Oncol*. 2012;2:41. PubMed PMID: 22649787; PubMed Central PMCID: PMC3355932.
19. Inghirami G, Pileri SA, European T-Cell Lymphoma Study Group. Anaplastic large-cell lymphoma. *Semin Diagn Pathol*. 2011 Aug;28(3):190-201. PubMed PMID: 21850985.
20. Barreca A, Lasorsa E, Riera L, Machiorlatti R, **Piva R**, Ponzoni M, Kwee I, Bertoni F, Piccaluga PP, Pileri SA, Inghirami G, European T-Cell Lymphoma Study Group. Anaplastic lymphoma kinase in human cancer. *J Mol Endocrinol*. 2011 Aug;47(1):R11-23. PubMed PMID: 21502284.
21. **Piva R**, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, Fornari A, Martinoglio B, Medico E, Zamò A, Facchetti F, Ponzoni M, Geissinger E, Rosenwald A, Müller-Hermelink HK, De Wolf-Peters C, Piccaluga PP, Pileri S, Neri A, Inghirami G. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. *J Clin Oncol*. 2010 Mar 20;28(9):1583-90. PubMed PMID: 20159827.
22. Piccaluga PP, Gazzola A, Mannu C, Agostinelli C, Bacci F, Sabattini E, Sagraro C, **Piva R**, Roncolato F, Inghirami G, Pileri SA. Pathobiology of anaplastic large cell lymphoma. *Adv Hematol*. 2010; PubMed PMID: 21331150; PubMed Central PMCID: PMC3038421.

23. Belardo G, **Piva R**, Santoro MG. Heat stress triggers apoptosis by impairing NF-kappaB survival signaling in malignant B cells. *Leukemia*. 2010 Jan;24(1):187-96. PubMed PMID: 19924145.
24. Fornari A, **Piva R**, Chiarle R, Novero D, Inghirami G. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?. *Hematol Oncol*. 2009 Dec;27(4):161-70. PubMed PMID: 19358142.
25. Regis G, Icardi L, Conti L, Chiarle R, **Piva R**, Giovarelli M, Poli V, Novelli F. IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. *Leukemia*. 2009 Nov;23(11):2102-8. PubMed PMID: 19626047.
26. **Piva R**, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Gai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. *Blood*. 2008 Mar 1;111(5):2765-75. PubMed PMID: 18057228.
27. Battaglia F, Delfino S, Merello E, Puppo M, **Piva R**, Varesio L, Bosco MC. Hypoxia transcriptionally induces macrophage-inflammatory protein-3alpha/CCL-20 in primary human mononuclear phagocytes through nuclear factor (NF)-kappaB. *J Leukoc Biol*. 2008 Mar;83(3):648-62. PubMed PMID: 18089854.
28. Chiarle R, Voena C, Ambrogio C, **Piva R**, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. *Nat Rev Cancer*. 2008 Jan;8(1):11-23. PubMed PMID: 18097461.
29. Di Stefano P, Damiano L, Cabodi S, Aramu S, Tordella L, Pradouroux A, **Piva R**, Cavallo F, Forni G, Silengo L, Tarone G, Turco E, Defilippi P. p140Cas protein suppresses tumour cell properties, regulating Csk and Src kinase activity. *EMBO J*. 2007 Jun 20;26(12):2843-55. PubMed PMID: 17525734; PubMed Central PMCID: PMC1894765.
30. Primo L, di Blasio L, Roca C, Droetto S, **Piva R**, Schaffhausen B, Bussolino F. Essential role of PDK1 in regulating endothelial cell migration. *J Cell Biol*. 2007 Mar 26;176(7):1035-47. PubMed PMID: 17371830; PubMed Central PMCID: PMC2064087.
31. **Piva R**, Pellegrino E, Inghirami G. Identification and validation of the anaplastic large cell lymphoma signature. *Adv Exp Med Biol*. 2007;604:129-36. PubMed PMID: 17695725.
32. **Piva R**, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, Costa G, Ruggeri BA, Cheng M, Chiarle R, Palestro G, Neri A, Inghirami G. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. *J Clin Invest*. 2006 Dec;116(12):3171-82. PubMed PMID: 17111047; PubMed Central PMCID: PMC1636692.
33. Ciucci A, Gianferretti P, **Piva R**, Guyot T, Snape TJ, Roberts SM, Santoro MG. Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkkappaB kinase/nuclear factor-kappaB pathway. *Mol Pharmacol*. 2006 Nov;70(5):1812-21. PubMed PMID: 16908599.
34. **Piva R**, Belardo G, Santoro MG. NF-kappaB: a stress-regulated switch for cell survival. *Antioxid Redox Signal*. 2006 Mar-Apr;8(3-4):478-86. PubMed PMID: 16677091.
35. **Piva R**, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. *Blood*. 2006 Jan 15;107(2):689-97. PubMed PMID: 16189272; PubMed Central PMCID: PMC1895619.
36. Ambrogio C, Voena C, Manazza AD, **Piva R**, Riera L, Barberis L, Costa C, Tarone G, Defilippi P, Hirsch E, Boeri Erba E, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. *Blood*. 2005 Dec 1;106(12):3907-16. PubMed PMID: 16105984; PubMed Central PMCID: PMC1895100.
37. Inghirami G, Chiarle R, Simmons WJ, **Piva R**, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. *Cell Cycle*. 2005 Sep;4(9):1131-3. PubMed PMID: 16082218.
38. **Piva R**, Gianferretti P, Ciucci A, Taulli R, Belardo G, Santoro MG. 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. *Blood*. 2005 Feb 15;105(4):1750-8. PubMed PMID: 15498850.
39. Bendotti C, Atzori C, **Piva R**, Tortarolo M, Strong MJ, DeBiasi S, Migheli A. Activated p38MAPK is a novel component of the intracellular inclusions found in human amyotrophic lateral sclerosis and mutant SOD1 transgenic mice. *J Neuropathol Exp Neurol*. 2004 Feb;63(2):113-9. PubMed PMID: 14989597.
40. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, Simmons WJ, Dhall G, Howes J, **Piva R**, Inghirami G. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. *Blood*. 2003 Mar 1;101(5):1919-27. PubMed PMID: 12424201.
41. **Piva R**, Liu J, Chiarle R, Podda A, Pagano M, Inghirami G. In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. *Mol Cell Biol*. 2002 Dec;22(23):8375-87. PubMed PMID: 12417738; PubMed Central PMCID: PMC134052.
42. Schiffer D, Cavalla P, Fiano V, Ghimenti C, **Piva R**. Inverse relationship between p27/Kip1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot. *Neurosci Lett*. 2002 Aug 9;328(2):125-8. PubMed PMID: 12133571.
43. Chiarle R, Fan Y, **Piva R**, Boggino H, Skolnik J, Novero D, Palestro G, De Wolf-Peeters C, Chilosi M, Pagano M, Inghirami G. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. *Am J Pathol*. 2002 Apr;160(4):1457-66. PubMed PMID: 11943729; PubMed Central PMCID: PMC1867227.
44. Zamo A, Chiarle R, **Piva R**, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. *Oncogene*. 2002 Feb 7;21(7):1038-47. PubMed PMID: 11850821.
45. Atzori C, Ghetti B, **Piva R**, Srinivasan AN, Zolo P, Delisle MB, Mirra SS, Migheli A. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. *J Neuropathol Exp Neurol*. 2001 Dec;60(12):1190-7. PubMed PMID: 11764091.
46. Audero E, Cascone I, Zanon I, Previtali SC, **Piva R**, Schiffer D, Bussolino F. Expression of angiopoietin-1 in human glioblastomas regulates tumor-induced angiogenesis: in vivo and in vitro studies. *Arterioscler Thromb Vasc Biol*. 2001 Apr;21(4):536-41. PubMed PMID: 11304469.
47. Chilosi M, Chiarle R, Lestani M, Menestrina F, Montagna L, Ambrosetti A, Prolla G, Pizzolo G, Doglioni C, **Piva R**, Pagano M, Inghirami G. Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. *Br J Haematol*. 2000 Oct;111(1):263-71. PubMed PMID: 11091210.
48. Cavalla P, **Piva R**, Bortolotto S, Grosso R, Cancelli I, Chiò A, Schiffer D. p27/kip1 expression in oligodendrogliomas and its possible prognostic role. *Acta Neuropathol*. 1999 Dec;98(6):629-34. PubMed PMID: 10603039.
49. Migheli A, Atzori C, **Piva R**, Tortarolo M, Girelli M, Schiffer D, Bendotti C. Lack of apoptosis in mice with ALS. *Nat Med*. 1999 Sep;5(9):966-7. PubMed PMID: 10470053.
50. Migheli A, **Piva R**, Casolino S, Atzori C, Dlouhy SR, Ghetti B. A cell cycle alteration precedes apoptosis of granule cell precursors in the weaver mouse cerebellum. *Am J Pathol*. 1999 Aug;155(2):365-73. PubMed PMID: 10433930; PubMed Central PMCID: PMC1866868.
51. **Piva R**, Cancelli I, Cavalla P, Bortolotto S, Dominguez J, Draetta GF, Schiffer D. Proteasome-dependent degradation of p27/kip1 in gliomas. *J Neuropathol Exp Neurol*. 1999 Jul;58(7):691-6. PubMed PMID: 10411338.
52. Schiffer D, Bortolotto S, Bosone I, Cancelli I, Cavalla P, Schiffer P, **Piva R**. Cell-cycle inhibitor p27/Kip-1 expression in non-astrocytic and non-oligodendrocytic human nervous system tumors. *Neurosci Lett*. 1999 Apr 2;264(1-3):29-32. PubMed PMID: 10320006.
53. Migheli A, Cordera S, Bendotti C, Atzori C, **Piva R**, Schiffer D. S-100beta protein is upregulated in astrocytes and motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis. *Neurosci Lett*. 1999 Feb 12;261(1-2):25-8. PubMed PMID: 10081918.

54. Wei J, Hodes ME, **Piva R**, Feng Y, Wang Y, Ghetti B, Dlouhy SR. Characterization of murine Girk2 transcript isoforms: structure and differential expression. *Genomics*. 1998 Aug 1;51(3):379-90. PubMed PMID: 9721208.
55. Cavalla P, Dutto A, **Piva R**, Richiardi P, Grosso R, Schiffer D. Cyclin D1 expression in gliomas. *Acta Neuropathol*. 1998 Feb;95(2):131-5. PubMed PMID: 9498046.
56. **Piva R**, Bortolotto S, Cordera S, Grosso R, Richiardi P, Dutto A, Schiffer D. CDKN2/p16 inactivation and p16 immunohistochemistry in astrocytic gliomas. *Int J Oncol*. 1998 Jan;12(1):55-8. PubMed PMID: 9454886.
57. Migheli A, **Piva R**, Atzori C, Troost D, Schiffer D. c-Jun, JNK/SAPK kinases and transcription factor NF-kappa B are selectively activated in astrocytes, but not motor neurons, in amyotrophic lateral sclerosis. *J Neuropathol Exp Neurol*. 1997 Dec;56(12):1314-22. PubMed PMID: 9413280.
58. Migheli A, **Piva R**, Wei J, Attanasio A, Casolino S, Hodes ME, Dlouhy SR, Bayer SA, Ghetti B. Diverse cell death pathways result from a single missense mutation in weaver mouse. *Am J Pathol*. 1997 Dec;151(6):1629-38. PubMed PMID: 9403713; PubMed Central PMCID: PMC1858371.
59. **Piva R**, Cavalla P, Bortolotto S, Cordera S, Richiardi P, Schiffer D. p27/kip1 expression in human astrocytic gliomas. *Neurosci Lett*. 1997 Oct 3;234(2-3):127-30. PubMed PMID: 9364514.
60. Migheli A, Mongini T, Doriguzzi C, Chiadò-Piat L, **Piva R**, Ugo I, Palmucci L. Muscle apoptosis in humans occurs in normal and denervated muscle, but not in myotonic dystrophy, dystrophinopathies or inflammatory disease. *Neurogenetics*. 1997 Sep;1(2):81-7. PubMed PMID: 10732808.
61. Schiffer D, Dutto A, Cavalla P, Chiò A, Migheli A, **Piva R**. Role of apoptosis in the prognosis of oligodendrogliomas. *Neurochem Int*. 1997 Aug;31(2):245-50. PubMed PMID: 9220457.
62. Wei J, Dlouhy SR, Bayer S, **Piva R**, Verina T, Wang Y, Feng Y, Dupree B, Hodes ME, Ghetti B. In situ hybridization analysis of Girk2 expression in the developing central nervous system in normal and weaver mice. *J Neuropathol Exp Neurol*. 1997 Jul;56(7):762-71. PubMed PMID: 9210872.
63. Migheli A, Cavalla P, **Piva R**, Giordana MT, Schiffer D. bcl-2 protein expression in aged brain and neurodegenerative diseases. *Neuroreport*. 1994 Oct 3;5(15):1906-8. PubMed PMID: 7841373.

Dichiarazioni

Dichiaro di consentire il trattamento dei dati personali e le pubblicazioni dell'elenco dei titoli e delle pubblicazioni scientifiche (sito del Ministero, dell'Unione europea e dell'università sede della procedura) nonché degli atti relativi alla procedura di abilitazione, dei giudizi individuali espressi da ciascun commissario e dei pareri pro veritate (sito del Ministero) secondo quanto previsto dal presente decreto, nel rispetto del DLgs n. 196 del 2003.